

CERTIFIED EXTRACT COPY OF RESOLUTION PASSED AT THE IPO COMMITTEE MEETING OF VEEDA CLINICAL RESEARCH LIMITED HELD ON FRIDAY 31ST JANUARY, 2025 AT THE CORPORATE OFFICE OF THE COMPANY SITUATED AT SATYAMEV CORPORATE, NR. SHALIN BUNGLOWS, CORPORATE ROAD, PRAHLADNAGAR, AHMEDABAD - 380015 AT 1130 HOURS.

APPROVE AND ADOPT THE DRAFT RED HERRING PROSPECTUS

“RESOLVED THAT the Draft Red Herring Prospectus for the proposed initial public offering of equity shares of Veeda Clinical Research Limited (the “Company”) of face value of ₹ 2 each (the “Equity Shares”) comprising a fresh issue of Equity Shares by the Company (“Fresh Issue”) and an offer for sale of Equity Shares by certain existing shareholders of the Company (the “Selling Shareholders”) (the “Offer for Sale”) and together with the Fresh Issue, the “Offer”, containing as required under the notified provisions of the Companies Act, 2013 as amended and the rules and regulations framed there under, the “Companies Act”), containing disclosures as required under the provisions of the Securities Contracts (Regulation) Act, 1956 (and the applicable rules thereunder), each as amended, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and other applicable law, a copy of which is placed before the meeting, be and is hereby approved and adopted for filing with the Securities and Exchange Board of India (the “SEBI”) and the relevant stock exchanges, as the case may be, and such other governmental or supervisory authorities or persons as may be required, in accordance with the applicable provisions of the Companies Act, the SEBI ICDR Regulations and other applicable law;

RESOLVED FURTHER THAT Dr. Mahesh Bhalgat, Managing Director or Mr. Nirmal Bhatia, Company Secretary & Chief Financial Officer of the Company, be and hereby authorized to sign the said Draft Red Herring Prospectus on behalf of the Company and file the same with the SEBI for their observations and with the relevant stock exchanges for obtaining their in-principle approval and for listing purposes and such other authorities or persons as may be required, issue such certificates and confirmations as may be required and undertake such other necessary steps to implement the afore going resolutions;

RESOLVED FURTHER THAT the IPO Committee, as constituted on 16th July, 2021, be and is hereby authorized to undertake, approve and adopt any subsequent changes, correction, updates, alterations, revisions, modifications or amendments in the Draft Red Herring Prospectus in accordance with the applicable law and regulations prior to filing with SEBI;

RESOLVED FURTHER THAT, IPO Committee be and is hereby authorized to do all such acts, deeds, matters and things as may be necessary or desirable for such purpose, including, without limitation, to settle any questions, difficulties or doubts that may arise in relation thereto;

RESOLVED FURTHER THAT Dr. Mahesh Bhalgat, Managing Director or Mr. Nirmal Bhatia, Company Secretary & Chief Financial Officer of the Company, be and is hereby individually and severally authorized to represent, sign / e-sign, e-file all e-forms to the, Registrar of Companies, RBI FIRMS portal registration, any government body, semi government body/authority, Corporations, Institutes, joint venture agreement, technical agreement and all related forms, letters, share certificates, etc. and to do the necessary acts, deeds, negotiate, approve, authorize, empower, give power of attorney to any officer of the Company, nominate any officer/person of the Company to do so, sign any forms, letters, agreements, etc. and do all such acts as may be necessary to appear before and represent the Company with all statutory bodies as required.”

**CERTIFIED COPY
FOR, VEEDA CLINICAL RESEARCH LIMITED**

**DR. MAHESH BHALGAT
GROUP CEO AND MANAGING DIRECTOR
DIN: 07253670**